Tag: relapsed refractory multiple myeloma

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% overall response rate seen in patients on the recommended dosage of teclistamab that persisted and increased overtime. Evidence Rating Level: 1 (Excellent) Study Rundown: Multiple myeloma is the second most common blood...
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median progression-free survival and estimated survival rates two years after randomization in favor of the isatuximab group. Evidence Rating Level: 1 (Excellent) Study Rundown: Multiple myeloma (MM) remains an incurable hematologic malignancy, typically...